The Journal of Urology
Volume 181, Issue 6 , Pages 2430-2437, June 2009

Management of the Adrenal Gland During Partial Nephrectomy

  • Brian R. Lane

      Affiliations

    • Corresponding Author InformationCorrespondence and requests for reprints: Glickman Urological Institute, The Cleveland Clinic Foundation, 9500 Euclid Ave., A100, Cleveland, Ohio 44195 (telephone: 216-445-7242; FAX: 216-445-2267)
    • Recipient of a Research Scholar grant from the American Urological Association Foundation.
  • ,
  • Ho-Yee Tiong

      Affiliations

    • Nothing to disclose.
  • ,
  • Steven C. Campbell

      Affiliations

    • Financial interest and/or other relationship with Novartis, Pfizer and Sanofi Aventis.
  • ,
  • Amr F. Fergany

      Affiliations

    • Nothing to disclose.
  • ,
  • Christopher J. Weight

      Affiliations

    • Nothing to disclose.
  • ,
  • Benjamin T. Larson

      Affiliations

    • Nothing to disclose.
  • ,
  • Andrew C. Novick

      Affiliations

    • Nothing to disclose.
  • ,
  • Stuart M. Flechner

      Affiliations

    • Financial interest and/or other relationship with Novartis Pharmaceuticals, Wyeth Pharmaceuticals, Roche Pharmaceuticals, Genzyme Pharmaceuticals, Tc Land and Clinical Transplantation.

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio

Received 17 October 2008 published online 16 April 2009.

Purpose

Nephron sparing surgery is an increasingly used alternative to Robson's radical nephroadrenalectomy. The indications for adrenalectomy in patients undergoing partial nephrectomy are not clearly defined and some surgeons perform it routinely for large and/or upper pole renal tumors. We analyzed initial management and oncological outcomes of adrenal glands after open partial nephrectomy.

Materials and Methods

Institutional review board approval was obtained for this study. During partial nephrectomy the ipsilateral adrenal gland was resected if a suspicious adrenal nodule was noted on radiographic imaging, or if intraoperative findings indicated direct extension or metastasis.

Results

Concomitant adrenalectomy was performed in 48 of 2,065 partial nephrectomies (2.3%). Pathological analysis revealed direct invasion of the adrenal gland by renal cell carcinoma (1), renal cell carcinoma metastasis (2), other adrenal neoplasms (3) or benign tissue (42, 87%). During a median followup of 5.5 years only 15 patients underwent subsequent adrenalectomy (0.74%). Metachronous adrenalectomy was ipsilateral (10), contralateral (2) or bilateral (3), revealing metastatic renal cell carcinoma in 11 patients. Overall survival at 5 years in patients undergoing partial nephrectomy with or without adrenalectomy was 82% and 85%, respectively (p = 0.56).

Conclusions

Adrenalectomy should not be routinely performed during partial nephrectomy, even for upper pole tumors. We propose concomitant adrenalectomy only if a suspicious adrenal lesion is identified radiographically or invasion of the adrenal gland is suspected intraoperatively. Using these criteria adrenalectomy was avoided in more than 97% of patients undergoing partial nephrectomy. Even using such strict criteria only 13% of these suspicious adrenal nodules contained cancer. The rarity of metachronous adrenal metastasis and the lack of an observable benefit to concomitant adrenalectomy support adrenal preservation during partial nephrectomy except as previously outlined.

Key Words: carcinoma, renal cell, nephrectomy, adrenal glands, treatment outcome, surgical procedures, operative

Abbreviations and Acronyms: CT, computerized tomography, OPN, open partial nephrectomy, RCC, renal cell carcinoma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Study received institutional review board approval.

 Editor's Note: This article is the second of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 2834 and 2835.

PII: S0022-5347(09)00355-3

doi:10.1016/j.juro.2009.02.027

The Journal of Urology
Volume 181, Issue 6 , Pages 2430-2437, June 2009